Isis Pharmaceuticals to Present at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Investors Focused on Two Questions for ISIS Pharmaceuticals (ISIS), Needham & Company Notes
April 13, 2015 6:28 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $80 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) after spending several days on the road with ISIS management and found investor questions remarkably focused on two key areas.
The first area was the... More
